BSN CAPITAL PARTNERS Ltd Has $14.92 Million Stock Position in Intuitive Surgical, Inc. $ISRG

Key Points

• BSN CAPITAL PARTNERS Ltd significantly reduced its stake in Intuitive Surgical, decreasing its holdings by 68.2% to $14.92 million, making the stock its 8th largest position.
• Insiders have been active, with significant sales including Amy L. Ladd, who sold 335 shares, and Gary S. Guthart, who sold 29,360 shares, indicating potential shifts in confidence among company leadership.
• Recent analyst ratings for Intuitive Surgical show a predominance of "Buy" recommendations, with fourteen analysts rating it as such and a target price average of $589.43 despite a recent stock price drop of 3.2%.

BSN CAPITAL PARTNERS Ltd decreased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 68.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,624 shares of the medical equipment provider's stock after selling 59,376 shares during the quarter. Intuitive Surgical accounts for approximately 1.2% of BSN CAPITAL PARTNERS Ltd's holdings, making the stock its 8th largest position. BSN CAPITAL PARTNERS Ltd's holdings in Intuitive Surgical were worth $14,917,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ISRG. Chilton Capital Management LLC grew its stake in shares of Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares in the last quarter. Elite Financial Inc. bought a new position in Intuitive Surgical during the first quarter valued at about $26,000. LFA Lugano Financial Advisors SA bought a new position in Intuitive Surgical during the first quarter valued at about $30,000. TD Capital Management LLC boosted its stake in Intuitive Surgical by 300.0% during the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 45 shares in the last quarter. Finally, 1248 Management LLC bought a new position in Intuitive Surgical during the first quarter valued at about $30,000. Institutional investors own 83.64% of the company's stock.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amy L. Ladd sold 335 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $440.69, for a total transaction of $147,631.15. Following the completion of the sale, the director directly owned 739 shares in the company, valued at approximately $325,669.91. This trade represents a 31.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gary S. Guthart sold 29,360 shares of the firm's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $472.49, for a total value of $13,872,306.40. Following the sale, the insider owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 45,224 shares of company stock worth $21,716,492. 0.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Intuitive Surgical in a research note on Wednesday. Zacks Research cut Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Truist Financial raised their target price on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Wells Fargo & Company raised their target price on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research note on Wednesday, July 23rd. Finally, BTIG Research reaffirmed a "buy" rating and set a $571.00 target price on shares of Intuitive Surgical in a research note on Wednesday, October 1st. Fourteen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of "Moderate Buy" and an average price target of $589.43.

Intuitive Surgical Stock Down 3.2%

NASDAQ:ISRG opened at $429.59 on Friday. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00. The firm has a market capitalization of $154.00 billion, a price-to-earnings ratio of 59.91, a price-to-earnings-growth ratio of 4.51 and a beta of 1.61. The stock has a fifty day simple moving average of $458.68 and a 200 day simple moving average of $497.91.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same quarter last year, the company posted $1.78 EPS. Intuitive Surgical's revenue for the quarter was up 21.4% on a year-over-year basis. Equities analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.